Eli Lilly reported a 54% year-over-year revenue growth to $17.6B in Q3. Analysts project tirzepatide as the top-selling drug by 2030. The company raised its quarterly dividend by 15% to $1.73 per share, with a 16% annual increase over the past five years.

Research shows that dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts. Dividend growers in the S&P 500 achieved higher average annual returns with lower volatility than non-payers or cutters.

Eli Lilly stands out as a strong choice for dividend growth investing due to its robust growth and consistent increases. The company ranks among the world’s largest pharmaceutical companies by revenue and holds the highest market capitalization in the sector, hitting $1 trillion in November.

Tirzepatide, Eli Lilly’s key drug, outperforms competitors in the GLP-1 market for diabetes and obesity. The drug achieved around 20% weight loss in head-to-head trials, positioning Lilly to compete effectively in the market.

Eli Lilly declared its first-quarter dividend of $1.73 per share, a 15% increase. The company has paid dividends for 55 consecutive years and raised them for the last 11 years, showcasing its commitment to rewarding shareholders with consistent growth.

Americans underestimate retirement needs but data shows that one habit can double savings. The habit, unrelated to income or saving methods, significantly impacts retirement savings and is surprisingly easy to adopt.

Read more at Yahoo Finance: Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026